Indiplon: The development of a new hypnotic

David N. Neubauer

doi:10.1517/13543784.14.10.1269

Indiplon: The development of a new hypnotic

David N. Neubauer

School of Medicine

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Indiplon is a short-acting hypnotic that is currently being developed as a treatment for insomnia by Neurocrine Biosciences and Pfizer, and is expected to be marketed in mid-2006. It is a high-affinity allosteric potentiator of GABA_A responses that demonstrates preference for α₁, subunit-containing GABA_A receptors. Indiplon will be an addition to the general category of newer-generation hypnotics that now includes zaleplon, zolpidem, zopiclone and eszopiclone. Clinical trials were carried out with an immediate-release capsule and a modified-release tablet and demonstrate very positive efficacy and safety profiles. The major challenge will be developing a commercial success in the crowded insomnia treatment marketplace.

Original language	English (US)
Pages (from-to)	1269-1276
Number of pages	8
Journal	Expert Opinion on Investigational Drugs
Volume	14
Issue number	10
DOIs	https://doi.org/10.1517/13543784.14.10.1269
State	Published - Oct 1 2005

Keywords

GABA receptors
Hypnotic
Indiplon
Insomnia
Modified release
Nonbenzodiazepine
Sleep disorders
α selective

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543784.14.10.1269

Cite this

@article{e75c8b9493c549aab728fbdc5badea29,

title = "Indiplon: The development of a new hypnotic",

abstract = "Indiplon is a short-acting hypnotic that is currently being developed as a treatment for insomnia by Neurocrine Biosciences and Pfizer, and is expected to be marketed in mid-2006. It is a high-affinity allosteric potentiator of GABAA responses that demonstrates preference for α1, subunit-containing GABAA receptors. Indiplon will be an addition to the general category of newer-generation hypnotics that now includes zaleplon, zolpidem, zopiclone and eszopiclone. Clinical trials were carried out with an immediate-release capsule and a modified-release tablet and demonstrate very positive efficacy and safety profiles. The major challenge will be developing a commercial success in the crowded insomnia treatment marketplace.",

keywords = "GABA receptors, Hypnotic, Indiplon, Insomnia, Modified release, Nonbenzodiazepine, Sleep disorders, α selective",

author = "Neubauer, {David N.}",

year = "2005",

month = oct,

day = "1",

doi = "10.1517/13543784.14.10.1269",

language = "English (US)",

volume = "14",

pages = "1269--1276",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

TY - JOUR

T1 - Indiplon

T2 - The development of a new hypnotic

AU - Neubauer, David N.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Indiplon is a short-acting hypnotic that is currently being developed as a treatment for insomnia by Neurocrine Biosciences and Pfizer, and is expected to be marketed in mid-2006. It is a high-affinity allosteric potentiator of GABAA responses that demonstrates preference for α1, subunit-containing GABAA receptors. Indiplon will be an addition to the general category of newer-generation hypnotics that now includes zaleplon, zolpidem, zopiclone and eszopiclone. Clinical trials were carried out with an immediate-release capsule and a modified-release tablet and demonstrate very positive efficacy and safety profiles. The major challenge will be developing a commercial success in the crowded insomnia treatment marketplace.

AB - Indiplon is a short-acting hypnotic that is currently being developed as a treatment for insomnia by Neurocrine Biosciences and Pfizer, and is expected to be marketed in mid-2006. It is a high-affinity allosteric potentiator of GABAA responses that demonstrates preference for α1, subunit-containing GABAA receptors. Indiplon will be an addition to the general category of newer-generation hypnotics that now includes zaleplon, zolpidem, zopiclone and eszopiclone. Clinical trials were carried out with an immediate-release capsule and a modified-release tablet and demonstrate very positive efficacy and safety profiles. The major challenge will be developing a commercial success in the crowded insomnia treatment marketplace.

KW - GABA receptors

KW - Hypnotic

KW - Indiplon

KW - Insomnia

KW - Modified release

KW - Nonbenzodiazepine

KW - Sleep disorders

KW - α selective

UR - http://www.scopus.com/inward/record.url?scp=27144505803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144505803&partnerID=8YFLogxK

U2 - 10.1517/13543784.14.10.1269

DO - 10.1517/13543784.14.10.1269

M3 - Article

C2 - 16185169

AN - SCOPUS:27144505803

SN - 1354-3784

VL - 14

SP - 1269

EP - 1276

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 10

ER -

Indiplon: The development of a new hypnotic

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this